Cannabinoids pp 691-717 | Cite as

Cannabinoid Tolerance and Dependence

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 168)


The use of marijuana for recreational and medicinal purposes has resulted in a large prevalence of chronic marijuana users. Consequences of chronic cannabinoid administration include profound behavioral tolerance and withdrawal symptoms upon drug cessation. A marijuana withdrawal syndrome is only recently gaining acceptance as being clinically significant. Similarly, laboratory animals exhibit both tolerance and dependence following chronic administration of cannabinoids. These animal models are being used to evaluate the high degree of plasticity that occurs at the molecular level in various brain regions following chronic cannabinoid exposure. In this review, we describe recent advances that have increased our understanding of the impact of chronic cannabinoid administration on cannabinoid receptors and their signal transduction pathways. Additionally, we discuss several potential pharmacotherapies that have been examined to treat marijuana dependence.


Cannabinoid Dependence Marijuana THC Withdrawal Tolerance Rimonabant Cannabis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aceto M, Scates S, Lowe J, Martin B (1995) Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 282:R1–R2PubMedCrossRefGoogle Scholar
  2. Aceto M, Scates S, Lowe J, Martin B (1996) Dependence on ⊲9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290–1295PubMedGoogle Scholar
  3. Aceto MD, Scates SM, Razdan RK, Martin BR (1998) Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther 287:598–605PubMedGoogle Scholar
  4. Aceto MD, Scates SM, Martin BB (2001) Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol 416:75–81PubMedCrossRefGoogle Scholar
  5. Anthony J, Warner L, Kessler R (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 2:244–268Google Scholar
  6. Bass C, Welch S, Martin B (2004) Reversal of delta(9)-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors. Eur J Pharmacol 496:99–108PubMedCrossRefGoogle Scholar
  7. Bass CE, Martin BR (2000) Time course for the induction and maintenance of tolerance to delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend 60:113–119PubMedGoogle Scholar
  8. Beardsley PM, Martin BR (2000) Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after delta(9)-tetrahydrocannabinol withdrawal. Eur J Pharmacol 387:47–53PubMedCrossRefGoogle Scholar
  9. Beardsley PM, Balster RL, Harris LS (1986) Dependence on tetrahydrocannabinol in rhesus monkeys. J Pharmacol Exp Ther 239:311–319PubMedGoogle Scholar
  10. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, Le Fur G, Casellas P (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312:637–641PubMedGoogle Scholar
  11. Braida D, Pozzi M, Cavallini R, Sala M (2001a) Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 104:923–926PubMedCrossRefGoogle Scholar
  12. Braida D, Pozzi M, Parolaro D, Sala M (2001b) Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol 413:227–234PubMedCrossRefGoogle Scholar
  13. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ (1999) Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73:2447–2459PubMedCrossRefGoogle Scholar
  14. Budney AJ, Novy PL, Hughes JR (1999) Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94:1311–1322PubMedCrossRefGoogle Scholar
  15. Budney AJ, Hughes JR, Moore BA, Novy PL (2001) Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 58:917–924PubMedGoogle Scholar
  16. Budney AJ, Moore BA, Vandrey RG, Hughes JR (2003) The time course and significance of cannabis withdrawal. J Abnorm Psychol 112:393–402PubMedCrossRefGoogle Scholar
  17. Burkey TH, Quock RM, Consroe P, Roeske WR, Yamamura HI (1997) Δ9-TetraHydro-Cannabinol is a partial agonist of cannabinoid receptors in mouse brain.Eur J Pharmacol 323:R3–R4PubMedCrossRefGoogle Scholar
  18. Caberlotto L, Rimondini R, Hansson A, Eriksson S, Heilig M (2004) Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift? Neuropsychopharmacology 29:15–22PubMedCrossRefGoogle Scholar
  19. Castane A, Robledo P, Matifas A, Kieffer BL, Maldonado R (2003) Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci 17:155–159PubMedCrossRefGoogle Scholar
  20. Castane A, Maldonado R, Valverde O (2004) Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice. Br J PharmacolGoogle Scholar
  21. Chaperon F, Thiebot MH (1999) Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13:243–281PubMedGoogle Scholar
  22. Cook SA, Lowe JA, Martin BR (1998) CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150–1156PubMedGoogle Scholar
  23. Cornelius JR, Salloum IM, Haskett RF, Ehler JG, Jarrett PJ, Thase ME, Perel JM (1999) Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav 24:111–114PubMedCrossRefGoogle Scholar
  24. Costa B, Giagnoni G, Colleoni M (2000) Precipitated and spontaneous withdrawal in rats tolerant to anandamide. Psychopharmacology (Berl) 149:121–128PubMedCrossRefGoogle Scholar
  25. Coutts AA, Anavi-Goffer S, Ross RA, MacEwan DJ, Mackie K, Pertwee RG, Irving AJ (2001) Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci 21:2425–2433PubMedGoogle Scholar
  26. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98:9371–9376PubMedCrossRefGoogle Scholar
  27. Darmani NA, Pandya DK (2000) Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naïve mice. J Neural Transm 107:931–945PubMedCrossRefGoogle Scholar
  28. Davis MI, Ronesi J, Lovinger DM (2003) A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem 278:48973–48980PubMedGoogle Scholar
  29. De Vry J, Jentzsch KR, Kuhl E, Eckel G (2004) Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15:1–12PubMedGoogle Scholar
  30. Derkinderen P, Toutant M, Burgaya F, Le Bert M, Siciliano JC, de Franciscis V, Gelman M, Girault JA (1996) Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 273:1719–1722PubMedGoogle Scholar
  31. Derkinderen P, Ledent C, Parmentier M, Girault JA (2001a) Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J Neurochem 77:957–960PubMedCrossRefGoogle Scholar
  32. Derkinderen P, Toutant M, Kadare G, Ledent C, Parmentier M, Girault JA (2001b) Dual role of Fyn in the regulation of FAK+6,7 by cannabinoids in hippocampus. J Biol Chem 276:38289–38296PubMedGoogle Scholar
  33. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA (2003) Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23:2371–2382PubMedGoogle Scholar
  34. Dewey WL, Jenkins J, Rourke T, Harris LS (1972) The effects of chronic administration of trans-⊲9-tetrahydrocannabinol on behavior and the cardiovascular system. Arch Int Pharmacodyn Ther 198:118–131PubMedGoogle Scholar
  35. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernandez-Ruiz JJ (2000) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta-9-tetrahydrocannabinol-tolerant rats. J Neurochem 74:1627–1635PubMedGoogle Scholar
  36. DSM-IV (1994) Diagnostic and statistical manual of mental disorders: DSM-IV. American Psychiatric Association, WashingtonGoogle Scholar
  37. Fan F, Compton DR, Ward S, Melvin L, Martin BR (1994) Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther 271:1383–1390PubMedGoogle Scholar
  38. Fan F, Tao Q, Abood M, Martin BR (1996) Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res 706:13–20PubMedCrossRefGoogle Scholar
  39. Fattore L, Cossu G, Martellotta CM, Fratta W (2001) Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl) 156:410–416PubMedCrossRefGoogle Scholar
  40. FDA (2004) serzone. Cited 12 September (2004)Google Scholar
  41. Ferguson SS, Caron MG (1998) G protein-coupled receptor adaptation mechanisms. Semin Cell Dev Biol 9:119–127PubMedCrossRefGoogle Scholar
  42. Ferry L, Johnston JA (2003) Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. Int J Clin Pract 57:224–230PubMedGoogle Scholar
  43. Fielding S, Wilker J, Hynes M, Szewczak M, Novick WJ Jr, Lal H (1978) A comparison of clonidine with morphine for antinociceptive and antiwithdrawal actions. J Pharmacol Exp Ther 207:899–905PubMedGoogle Scholar
  44. Fraser JD (1949) Withdrawal symptoms in cannabis-indica addicts. Lancet 257:747–748Google Scholar
  45. Freedland CS, Whitlow CT, Miller MD, Porrino LJ (2002) Dose-dependent effects of delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse 45:134–142PubMedCrossRefGoogle Scholar
  46. Freedland CS, Whitlow CT, Smith HR, Porrino LJ (2003) Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naïve and-tolerant animals: a quantitative 2-[14C]deoxyglucose study. Brain Res 962:169–179PubMedCrossRefGoogle Scholar
  47. Galve-Roperh I, Rueda D, Gomez del Pulgar T, Velasco G, Guzman M (2002) Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 62:1385–1392PubMedCrossRefGoogle Scholar
  48. Garcia DE, Brown S, Hille B, Mackie K (1998) Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci 18:2834–2841PubMedGoogle Scholar
  49. Gardner EL (2002) Addictive potential of cannabinoids: the underlying neurobiology. Chem Phys Lipids 121:267–290PubMedCrossRefGoogle Scholar
  50. Gardner EL, Lowinson JH (1991) Marijuana’s interaction with brain reward systems—update 1991. Pharmacol Biochem Behav 40:571–580PubMedCrossRefGoogle Scholar
  51. Gardner EL, Paredes W, Smith D, Donner A, Milling C, Cohen A, Morrison D (1988) Facilitation of brain stimulation reward by D9-tetrahydrocannabinol. Psychopharmacology (Berl) 96:142–144PubMedGoogle Scholar
  52. Gardner EL, Paredes W, Smith D, Zukin RS (1989) Facilitation of brain stimulation reward by D9-tetrahydrocannabinol is mediated by an endogenous opioid mechanism. Adv Biosci 75:671–674Google Scholar
  53. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002) Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22:1146–1154PubMedGoogle Scholar
  54. Gold MS, Redmond DE Jr, Kleber HD (1978) Clonidine blocks acute opiate-withdrawal symptoms. Lancet 2:599–602PubMedGoogle Scholar
  55. Gomez del Pulgar T, Velasco G, Guzman M (2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347:369–373Google Scholar
  56. Gonzalez S, Fernandez-Ruiz J, Marzo VD, Hernandez M, Arevalo C, Nicanor C, Cascio MG, Ambrosio E, Ramos JA (2004) Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug Alcohol Depend 74:159–170PubMedGoogle Scholar
  57. Gossop M (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21:253–259PubMedGoogle Scholar
  58. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 141:385–394PubMedGoogle Scholar
  59. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 141:395–404PubMedGoogle Scholar
  60. Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW (2001) Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl) 155:171–179PubMedCrossRefGoogle Scholar
  61. Haney M, Bisaga A, Foltin RW (2003a) Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl) 166:77–85PubMedGoogle Scholar
  62. Haney M, Hart CL, Ward AS, Foltin RW (2003b) Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl) 165:157–165PubMedGoogle Scholar
  63. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29:158–170PubMedCrossRefGoogle Scholar
  64. Hill MN, Gorzalka BB, Choi JW (2004) Augmentation of the development of behavioral tolerance to cannabinoid administration through pavlovian conditioning. Neuropsychobiology 49:94–100PubMedCrossRefGoogle Scholar
  65. Hirschhorn ID, Rosecrans JA (1974) Morphine and Δ9-tetrahydrocannabinol: tolerance to the stimulus effects. Psychopharmacologia 36:243–253PubMedCrossRefGoogle Scholar
  66. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202PubMedCrossRefGoogle Scholar
  67. Hsieh C, Brown S, Derleth C, Mackie K (1999) Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73:493–501PubMedCrossRefGoogle Scholar
  68. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125:1567–1577PubMedCrossRefGoogle Scholar
  69. Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, Chavkin C, Mackie K (1999) Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 19:3773–3780PubMedGoogle Scholar
  70. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE (2004) Monitoring the Future national results on adolescent drug use: overview of key findings, 2003. National Institute on Drug Abuse, BethdesdaGoogle Scholar
  71. Jones RT, Benowitz N (1976) The 30-day trip—clinical studies of cannabis tolerance and dependence. In: Braude MC, Szara S, (eds) Pharmacology of Marihuana. Raven Press, New York, 627–642Google Scholar
  72. Jones RT, Benowitz N, Bachman J (1976) Clinical studies of cannabis tolerance and dependence. Ann NY Acad Sci 282:221–239PubMedGoogle Scholar
  73. Jones RT, Benowitz NL, Herning RI (1981) Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21:143S–152SPubMedGoogle Scholar
  74. Justinova Z, Tanda G, Redhi GH, Goldberg SR (2003) Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) 169:135–140PubMedCrossRefGoogle Scholar
  75. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, Rana GL, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76–81PubMedCrossRefGoogle Scholar
  76. Kaymakcalan K, Ayhan IH, Tulunay FC (1977) Naloxone-induced or postwithdrawal abstinence signs in Δ9-tetrahydrocannabinol-tolerant rats. Psychopharmacology (Berl) 55:243–249PubMedGoogle Scholar
  77. Kaymakcalan S, Deneau GA (1972) Some pharmacologic properties of synthetic Δ9-tetrahydrocannabinol. Acta Medica Turcica Suppl 1:5Google Scholar
  78. Kouznetsova M, Kelley B, Shen M, Thayer SA (2002) Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Mol Pharmacol 61:477–485PubMedCrossRefGoogle Scholar
  79. Krupnick JG, Benovic JL (1998) The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289–319PubMedCrossRefGoogle Scholar
  80. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1–2PubMedCrossRefGoogle Scholar
  81. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401–404PubMedCrossRefGoogle Scholar
  82. Lee MC, Smith FL, Stevens DL, Welch SP (2003) The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 305:593–599PubMedGoogle Scholar
  83. Leite JR, Carlini EA (1974) Failure to obtain “cannabis-directed behavior” and abstinence syndrome in rats chronically treated with cannabis sativa extracts. Psychopharmacologia 36:133–145PubMedCrossRefGoogle Scholar
  84. Lepore M, Vorel SR, Lowinson J, Gardner EL (1995) Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 56:2073–2080PubMedCrossRefGoogle Scholar
  85. Lepore M, Liu X, Savage V, Matalon D, Gardner EL (1996) Genetric differences in D9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci 58:365–0372CrossRefGoogle Scholar
  86. Lichtman AH, Wiley JL, LaVecchia KL, Neviaser ST, Arthrur DB, Wilson DM, Martin BR (1998) Acute and chronic cannabinoid effects: characterization of precipitated withdrawal in dogs. Eur J Pharmacol 357:139–148PubMedCrossRefGoogle Scholar
  87. Lichtman AH, Fisher J, Martin BR (2001a) Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine. Pharmacol Biochem Behav 69:181–188PubMedCrossRefGoogle Scholar
  88. Lichtman AH, Sheikh SM, Loh HH, Martin BR (2001b) Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298:1007–1014PubMedGoogle Scholar
  89. Lichtman AH, Varvel SA, Martin BR (2002) Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 66:269–285PubMedCrossRefGoogle Scholar
  90. Lichtman AH, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger D, Cravatt BF (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp TherGoogle Scholar
  91. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, Kunos G (2000) Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346:835–840PubMedGoogle Scholar
  92. Maldonado R (2002) Study of cannabinoid dependence in animals. Pharmacol Ther 95:153–164PubMedCrossRefGoogle Scholar
  93. Maldonado R, Rodriguez de Fonseca F (2002) Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 22:3326–3331PubMedGoogle Scholar
  94. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W (1998) Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85:327–330PubMedCrossRefGoogle Scholar
  95. Martin BR (2002) Identification of the endogenous cannabinoid system through integrative pharmacological approaches. J Pharmacol Exp Ther 301:790–796PubMedGoogle Scholar
  96. Martin BR, Sim-Selley LJ, Selley DE (2004) Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 25:325–330PubMedCrossRefGoogle Scholar
  97. McMillan DE, Dewey WL, Harris LS (1971) Characteristics of tetrahydrocannabinol tolerance. Ann NY Acad Sci 191:83–99Google Scholar
  98. McRae AL, Budney AJ, Brady KT (2003) Treatment of marijuana dependence: a review of the literature. J Subst Abuse Treat 24:369–376PubMedCrossRefGoogle Scholar
  99. Navarro M, Chowen J, Carrera MRA, del Arco I, Vallanua MA, Martin Y, Roberts AJ, Koob GF, Rodriguez de Fonseca F (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9:3397–3402PubMedGoogle Scholar
  100. Oliva JM, Ortiz S, Palomo T, Manzanares J (2004) Spontaneous cannabinoid withdrawal produces a differential time-related responsiveness in cannabinoid CB1 receptor gene expression in the mouse brain. J Psychopharmacol 18:59–65PubMedCrossRefGoogle Scholar
  101. Oviedo A, Glowa J, Herkenham M (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616:293–302PubMedCrossRefGoogle Scholar
  102. Pan X, Ikeda SR, Lewis DL (1998) SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 54:1064–1072PubMedGoogle Scholar
  103. Richmond R, Zwar N (2003) Review of bupropion for smoking cessation. Drug Alcohol Rev 22:203–220PubMedGoogle Scholar
  104. Rinaldi-Carmona M, Barth F, Hèaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Breliére JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244PubMedCrossRefGoogle Scholar
  105. Rinaldi-Carmona M, Le Duigou A, Oustric D, Barth F, Bouaboula M, Carayon P, Casellas P, Le Fur G (1998) Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther 287:1038–1047PubMedGoogle Scholar
  106. Rodriguez de Fonseca F, Carrera M, Navarro M, Koob K, Weiss F (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050–2054Google Scholar
  107. Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernandez-Ruiz JJ (1997) Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 46:100–108PubMedGoogle Scholar
  108. Romero J, Berrendero F, Garcia-Gil L, DeLa Cruz P, Ramos A, Fernandez-Ruiz JJ (1998a) Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist stimulated [35 s]guanylyl-5’-O-(thio)-triphosphate binding in the basal ganglia of rats. Neuroscience 84:1075–1083PubMedCrossRefGoogle Scholar
  109. Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes JA, Fernandez-Ruiz JJ, Ramos JA (1998b) Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30:298–308PubMedCrossRefGoogle Scholar
  110. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, Parolaro D (1994) Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: An in situ hybridization study. NeuroReport 5:2493–2496PubMedGoogle Scholar
  111. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D (1997) Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res 44:191–197PubMedGoogle Scholar
  112. Rubino T, Patrini G, Massi P, Fuzio D, Vigano D, Giagnoni G, Parolaro D (1998) Cannabinoid precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 285:813–819PubMedGoogle Scholar
  113. Rubino T, Vigano D, Costa B, Colleoni M, Parolaro D (2000a) Loss of cannabinoid-stimulated guanosine 5′-O-(3-[(35)S]thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. J Neurochem 75:2478–2484PubMedGoogle Scholar
  114. Rubino T, Vigano D, Massi P, Spinello M, Zagato E, Giagnoni G, Parolaro D (2000b) Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39:1331–1336PubMedCrossRefGoogle Scholar
  115. Rubino T, Vigano D, Zagato E, Sala M, Parolaro D (2000c) In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse 35:8–14PubMedCrossRefGoogle Scholar
  116. Rueda D, Galve-Roperh I, Haro A, Guzman M (2000) The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 58:814–820PubMedGoogle Scholar
  117. Sanchez C, Galve-Roperh I, Rueda D, Guzman M (1998) Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 54:834–843PubMedGoogle Scholar
  118. Sanudo-Pena MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM (1997) Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 223:125–128PubMedGoogle Scholar
  119. Siegel S, Ramos BM (2002) Applying laboratory research: drug anticipation and the treatment of drug addiction. Exp Clin Psychopharmacol 10:162–183PubMedGoogle Scholar
  120. Sim LJ, Hampson RE, Deadwyler SA, Childers SR (1996a) Effects of chronic treatment with Δ9-tetrahydrocannabinol on cannabinoid-stimulated [35]GTPγS autoradiography in rat brain. J Neurosci 16:8057–8066PubMedGoogle Scholar
  121. Sim LJ, Selley DE, Xiao R, Childers SR (1996b) Differences in G-protein activation by µ-and ´-opioid, and cannabinoid, receptors in rat striatum. Eur J Pharmacol 307:97–105PubMedCrossRefGoogle Scholar
  122. Sim-Selley LJ (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15:91–119PubMedCrossRefGoogle Scholar
  123. Sim-Selley LJ, Martin BR (2002) Effect of chronic administration of R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl) methyl]pyrrolo[1,2,3-de]-1,4-b enzoxazinyl]-(1-naphthalenyl) methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 303:36–44PubMedCrossRefGoogle Scholar
  124. Sim-Selley LJ, Brunk LK, Selley DE (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135–143PubMedCrossRefGoogle Scholar
  125. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF (2002) A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A 99:8394–8399PubMedCrossRefGoogle Scholar
  126. Smith NT (2002) A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 97:621–632PubMedGoogle Scholar
  127. Takahashi RN, Singer G (1979) Self-administration of D9-tetrahydrocannabinol by rats. Pharmacol Biochem Behav 11:737–740PubMedCrossRefGoogle Scholar
  128. Takahashi RN, Singer G (1980) Effects of body weight levels on cannabis self-injection. Pharmacol Biochem Behav 13:877–881PubMedGoogle Scholar
  129. Tanda G, Goldberg SR (2003) Cannabinoids: reward, dependence, and underlying neurochemical mechanisms—a review of recent preclinical data. Psychopharmacology (Berl) 169:115–134PubMedCrossRefGoogle Scholar
  130. Tanda G, Munzar P, Goldberg SR (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3:1073–1074PubMedGoogle Scholar
  131. Tsou K, Patrick S, Walker JM (1995) Physical withdrawal in rats tolerant to Δ9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280:R13–R15PubMedCrossRefGoogle Scholar
  132. Tzavara ET, Valjent E, Firmo C, Mas M, Beslot F, Defer N, Roques BP, Hanoune J, Maldonado R (2000) Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum. Eur J Neurosci 12:1038–1046PubMedCrossRefGoogle Scholar
  133. Valjent E, Maldonado R (2000) A behavioural model to reveal place preference to delta9-tetrahydrocannabinol in mice. Psychopharmacology (Berl) 147:436–438PubMedCrossRefGoogle Scholar
  134. Valverde O, Maldonado R, Valjent E, Zimmer AM, Zimmer A (2000) Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 20:9284–9289PubMedGoogle Scholar
  135. Varvel SA, Cichewicz DL, Lichtman AH (2004) Interactions between cannabinoids and opioids. In: Wenger T (ed) Recent advances on pharmacology and physiology of cannabinoids research. Signpost, Keraka, 157–182Google Scholar
  136. Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR (2001) Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci 937:1–26PubMedGoogle Scholar
  137. Whitlow CT, Freedland CS, Porrino LJ (2003) Functional consequences of the repeated administration of delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend 71:169–177PubMedGoogle Scholar
  138. Wiesbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL (1996) An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 91:1469–1478PubMedCrossRefGoogle Scholar
  139. Wikler A (1976) Aspects of tolerance to and dependence on cannabis. Ann N Y Acad Sci 282:126–147PubMedGoogle Scholar
  140. Willoughby KA, Moore SF, Martin BR, Ellis EF (1997) The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282:243–247PubMedGoogle Scholar
  141. Wise RA (1996) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19:319–340PubMedCrossRefGoogle Scholar
  142. Zhuang S, Kittler J, Grigorenko EV, Kirby MT, Sim LJ, Hampson RE, Childers SR, Deadwyler SA (1998) Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res Mol Brain Res 62:141–149PubMedGoogle Scholar
  143. Zimmer A, Valjent E, Konig M, Zimmer AM, Robledo P, Hahn H, Valverde O, Maldonado R (2001) Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphind-deficient mice. J Neurosci 21:9499–9505PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Department of Pharmacology and ToxicologyVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations